BioLife Solutions, Inc. (NASDAQ:BLFS – Get Rating) EVP Aby J. Mathew sold 2,086 shares of BioLife Solutions stock in a transaction on Wednesday, March 1st. The shares were sold at an average price of $22.75, for a total value of $47,456.50. Following the transaction, the executive vice president now owns 271,601 shares of the company’s stock, valued at approximately $6,178,922.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
BioLife Solutions Trading Up 2.7 %
NASDAQ:BLFS opened at $23.93 on Monday. The business has a fifty day moving average price of $22.40 and a 200-day moving average price of $22.07. The firm has a market capitalization of $1.02 billion, a price-to-earnings ratio of -9.65 and a beta of 1.86. BioLife Solutions, Inc. has a one year low of $10.40 and a one year high of $26.96. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.68 and a quick ratio of 2.76.
Hedge Funds Weigh In On BioLife Solutions
Hedge funds and other institutional investors have recently modified their holdings of the stock. Allspring Global Investments Holdings LLC raised its position in shares of BioLife Solutions by 802.2% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,218 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 1,083 shares in the last quarter. Wipfli Financial Advisors LLC purchased a new stake in BioLife Solutions in the third quarter valued at about $29,000. Nisa Investment Advisors LLC boosted its holdings in BioLife Solutions by 439.3% in the third quarter. Nisa Investment Advisors LLC now owns 1,510 shares of the medical equipment provider’s stock worth $34,000 after acquiring an additional 1,230 shares in the last quarter. Point72 Hong Kong Ltd acquired a new position in shares of BioLife Solutions during the first quarter valued at about $36,000. Finally, Lazard Asset Management LLC acquired a new stake in BioLife Solutions in the 1st quarter worth approximately $45,000. Institutional investors own 89.82% of the company’s stock.
Analyst Ratings Changes
BioLife Solutions Company Profile
BioLife Solutions, Inc engages in the development, manufacture and marketing of bio preservation tools for cells and tissues. Its product offerings include proprietary hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs, generic blood stem cell freezing and cell thawing media products and custom product formulation and custom packaging services.
Featured Articles
- Get a free copy of the StockNews.com research report on BioLife Solutions (BLFS)
- MarketBeat Week in Review – 2/27 – 3/3
- The 3 Most Upgraded Stocks Are Reversing
- How to Find Blue Chip Dividend Stocks
- Zscaler, Inc Plummets, Is It Time To Buy The Dip?
- What is a Good Dividend Yield? How to Decide
Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.
